Skip to main content

Nanogen Wraps Up Share Conversion With Amplimedical

NEW YORK (GenomeWeb News) - Nanogen on June 30 issued 2.9 million shares of its common stock to Amplimedical upon conversion of a promissory note issued to that company, whose diagnostics division Nanogen acquired in the spring, according to documents filed with the Securities and Exchange Commission today.
 
Amplimedical received the convertible promissory note, dated May 1, when Nanogen acquired the company on April 19. The €6.1 million note ($7.5 million) was convertible into Nanogen common shares, the company said at the time.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.